Medical Digest & Congress Report

Dr. Alexandra Kautzky-Willer presents key insights on the patterns and prevention of cardiovascular diseases at the EASD 2026 Congress. This brief highlights clinical strategies for identifying cardiovascular risk patterns, implementing targeted early preventive measures, and optimizing long-term outcomes in patients with metabolic disorders.

Video: https://medicaldigest.org/scientific-contents/interview:patterns-and-prevention-cardiovascular-diseases

Dr. Claudio Scafoglio presents key insights into expanding the scope of SGLT-2 inhibition at the EASD 2026 Congress. This brief highlights real-world clinical data, underlying cellular mechanisms, and emerging evidence surrounding potential oncological applications and broader therapeutic frontiers of SGLT-2 inhibitors.

Video: https://medicaldigest.org/scientific-contents/interview:sglt-2-inhibitors-real-world-insights-mechanistic-and-oncological-frontiers

Dr. Gian Paolo Fadini presents key insights into interconnected organ protection with SGLT-2 inhibitors at the EASD 2026 Congress. This brief highlights clinical evidence on the cardiovascular, renal, and metabolic benefits of SGLT2 inhibition, emphasizing strategies to reduce overall risk and optimize long-term outcomes in patients with type 2 diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:making-connections-reduce-risk-cardiovascular-renal-and-metabolic-benefits-sglt-2-inhibitors-t2d

Dr. Matthias Blüher presents key insights from the EASD-EASO joint session on obesity management through different lenses at the EASD 2026 Congress. This brief highlights multidisciplinary approaches to weight management, combining endocrinology and obesity expertise to address metabolic complications, personalize therapeutic strategies, and improve long-term patient outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:obesity-management-through-different-lenses-easd-easo-joint-session

Dr. John Bernard Buse presents key updates from the joint ADA/EASD consensus report on the management of type 2 diabetes at the EASD 2026 Congress. This brief highlights updated clinical guidelines, person-centered management strategies, holistic care approaches, and evidence-based recommendations for glucose-lowering and cardiometabolic risk reduction.

Video: https://medicaldigest.org/scientific-contents/interview:adaeasd-consensus-report-management-type-2-diabetes

Dr. Cyrielle Caussy presents key insights from the EASD-EASL joint session on metabolic dysfunction-associated steatotic liver disease (MASLD) at the EASD 2026 Congress. This brief highlights early therapeutic approvals, real-world clinical data, and novel emerging treatments aimed at optimizing multidisciplinary care and improving outcomes for patients with MASLD and metabolic risk factors.

Video: https://medicaldigest.org/scientific-contents/interview:early-approvals-real-world-insights-and-emerging-therapies-masld-care-2

Dr. Paolo Sbraccia presents key insights into viewing obesity as a systemic disease and adopting a biology-driven approach to metabolic health at the EASD 2026 Congress. This brief highlights the pathophysiological progression from adiposity to systemic metabolic dysfunction, emphasizing targeted therapies and clinical strategies that look beyond weight loss to optimize overall cardiometabolic outcomes.

Video: https://medicaldigest.org/scientific-contents/interview:beyond-weight-loss-biology-driven-approach-metabolic-health-obesity-systemic-disease-adiposity-metabolic-dysfunction

Dr. Martin Haluzík presents key findings from the REIMAGINE 2 trial evaluating CagriSema at the EASD 2026 Congress. This brief highlights clinical data on the impact of dual amylin and GLP-1 receptor agonism on bone turnover markers, overall bone health, and metabolic parameters in participants with inadequately controlled type 2 diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:effect-cagrisema-bone-biomarkers-inadequately-controlled-type-2-diabetes-reimagine-2

Dr. Stefano Del Prato presents key findings from the Phase 3 TRIUMPH-2 trial evaluating retatrutide at the EASD 2026 Congress. This brief highlights clinical evidence on the glycemic efficacy, weight reduction outcomes, and safety profile of triple receptor agonism in adults living with obesity and type 2 diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:retatrutide-adults-obesity-and-type-2-diabetes-phase-3-triumph-2-trial

Dr. Katherine Tuttle presents key insights on cardiorenal protection in type 2 diabetes at the EASD 2026 Congress, drawing from both the FLOW and ACHIEVE-4 trials. This brief highlights novel proteomic biomarker analyses explaining the pathways of kidney protection in FLOW, alongside clinical data from the ACHIEVE-4 trial comparing the renal outcomes of oral orforglipron versus insulin glargine in high-risk patients.

Video: https://medicaldigest.org/scientific-contents/interview:renal-outcomes-and-cardiorenal-mechanisms-type-2-diabetes-highlights-flow-and-achieve-4-trials